About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

354,475 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/03/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 12/03/2020.

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clinicaltrials.gov identifier NCT04434196

Recruitment Status Recruiting

First Posted June 16, 2020

Last update posted August 28, 2020

Study Description

Brief summary:

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

  • Condition or Disease:Lymphoma, Non-Hodgkin
  • Intervention/Treatment: Drug: CC-99282
    Drug: Obinutuzumab
  • Phase: Phase 1
Detailed Description

All eligible subjects must be relapsed or refractory to at least 2 prior lines of therapy, one of which must have included an inhibitor of B-cell receptor signaling (approved Bruton's tyrosine kinase inhibitor [BTKi] or Phosphoinositide 3-kinase inhibitor [PI3Ki]) or venetoclax. The dose escalation (Part A) will evaluate the safety, tolerability, and PK of escalating doses of CC-99282 given in combination with intravenous obinutuzumab to determine the MTD and RP2D of CC-99282 when given in combination with obinutuzumab.The dose expansion (Part B) may occur at the MTD established in the dose escalation phase, or at an alternative tolerable dosing schedule, based on review of safety, PK and PD data from Part A.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 50 participants
  • Intervention Model: Sequential Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Phase 1B, Multicenter, Open-label Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Estimated Study Start Date: August 2020
  • Estimated Primary Completion Date: June 2024
  • Estimated Study Completion Date: May 2025
Arms and interventions
Arm Intervention/treatment
Experimental: CC-99282 + obinutuzumab
Escalating doses of CC-99282 administered orally once daily on intermittent schedules with obinutuzumab IV infusion 1000 mg up to 2 years in Part A. CC-99282 administered orally once daily at MTD or alternative tolerating dosing schedule with obinutuzumab IV infusion 1000 mg up to 2 years in Part B.
Drug: CC-99282
CC-99282

Drug: Obinutuzumab
Obinutuzumab
Outcome Measures
  • Primary Outcome Measures: 1. Dose Limiting Toxicity (DLT) [ Time Frame: Up to Cycle 2 Day 14 (each cycle is 28 days) ]
    Number of subjects with a DLT
  • 2. Maximum tolerated dose (MTD) [ Time Frame: Up to Cycle 2 Day 14 (each cycle is 28 days ]
    The highest dose of CC-99282 in combination with obinutuzumab associated with acceptable safety and tolerability
  • 3. Adverse Events (AEs) [ Time Frame: From first subjects first visit until 28 days after last subject discontinued study treatment ]
    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.
  • Secondary Outcome Measures: 1. Pharmacokinetics - Cmax [ Time Frame: Up to Cycle 2 Day 14 (each cycle is 28 days) ]
    Maximum observed plasma concentration
  • 2. Pharmacokinetics - AUC [ Time Frame: Up to Cycle 2 Day 14 (each cycle is 28 days) ]
    Area under the plasma concentration-time curve
  • 3. Pharmacokinetics - Tmax [ Time Frame: Up to Cycle 2 Day 14 (each cycle is 28 days) ]
    Time to Cmax
  • 4. Pharmacokinetics - t1/2 [ Time Frame: Up to Cycle 2 Day 14 (each cycle is 28 days) ]
    Terminal-phase elimination half-life
  • 5. Pharmacokinetics - CL/F [ Time Frame: Up to Cycle 2 Day 14 (each cycle is 28 days) ]
    Apparent total clearance of the drug from plasma after oral administration
  • 6. Pharmacokinetics - V/F [ Time Frame: Up to Cycle 2 Day 14 (each cycle is 28 days) ]
    Apparent volume of distribution during terminal phase after non-intravenous administration
  • 7. Objective response rate (ORR) [ Time Frame: Up to approximately 3 years ]
    Sum of complete response (CR), complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), partial response (PR), partial response with lymphocytosis (PRL) determined by iwCLL criteria
  • 8. Duration of response (DoR) [ Time Frame: Up to approximately 3 years ]
    Time from first documentation of response (≥ PR) to the first documentation of PD or death
  • 9. Progression free survival [ Time Frame: Up to approximately 3 years ]
    Time from first dose of CC-99282 to the first occurrence of disease progression or death from any cause
  • 10. Overall survival [ Time Frame: Up to approximately 3 years ]
    Time from first dose of CC-99282 to death from any cause
  • 11. Complete response with incomplete marrow recovery (CRi) [ Time Frame: Up to approximately 3 years ]
    As assessed by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
  • 12. Nodular partial response (nPR) [ Time Frame: Up to approximately 3 years ]
    As assessed by iwCL and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
  • 13. Partial response (PR) [ Time Frame: Up to approximately 3 years ]
    As assessed by iwC and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
  • 14. Partial response with lymphocytosis (PRL) [ Time Frame: Up to approximately 3 years ]
    As assessed by iwCLL and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

1. Subject is ≥18 years of age

2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

3. Must have a documented diagnosis of CLL/SLL requiring treatment (IwCLL Guidelines for
the Diagnosis and Treatment of CLL). In addition presence of clinically measurable
disease determined by at least one of the factors listed:

- nodal lesion that measures ≥ 1.5 cm in longest dimension (LD) and ≥ 1.0 cm in
longest perpendicular dimension (LPD), or

- spleen that measures ≥ 14 cm in longest vertical dimension (LVD) with a minimum
of 2 cm enlargement, or

- liver that measures ≥ 20 cm in LVD with a minimum of 2 cm enlargement, or

- peripheral blood B lymphocyte count > 5000/uL

4. All eligible subjects must be relapsed after or be refractory to >2 prior lines of
therapy one of which must have included an approved BTK inhibitor.

5. Must meet the following laboratory parameters:

1. Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3 or ≥ 1000 cells/mm3 if
secondary to bone marrow involvement by disease.

2. Platelet count ≥ 100,000 cells/mm3 (100 x 109/L) or ≥ 50,000 cells/mm3 (50 x
109/L) if secondary to bone marrow involvement by disease.

3. Serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) < 3.0 x upper limit of normal (ULN). 4. Serum bilirubin < 1.5 x ULN unless due to Gilbert's syndrome. 5. Calculated creatinine clearance of ≥ 60 ml/min. Exclusion Criteria: 1. Presence of any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. Prior allogeneic stem cell transplant (SCT)/bone marrow transplant within 12 months of signing the ICD. Subjects who received allogeneic SCT ≥ 12 months before signing the ICD may be eligible provided there is no ongoing graft-versus-host disease and no ongoing immune suppression therapy. 3. Subject has received prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to starting CC-99282. 4. Subject has received prior therapy with CRBN-modulating drug (eg, lenalidomide, avadomide/CC-122, pomalidomide) ≤ 4 weeks prior to starting CC-99282. 5. History of second malignancies with life expectancy of ≤ 2 years or requirement of therapy that would confound study results. 6. Peripheral neuropathy ≥ Grade 2. 7. History of hypersensitivity to lenalidomide, pomalidomide, thalidomide. 8. Impaired cardiac function or clinically significant cardiac disease. 9. Persistent diarrhea or malabsorption ≥ NCI CTCAE Grade 2, despite medical management. 10. Active disease transformation (ie, Richter's Syndrome) 11. Uncontrolled/active autoimmune hemolytic anemia or thrombocytopenia

Contacts and Locations
Contacts

Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Locations
Show 15 Study Locations
Sponsors and Collaborators

Celgene

Investigators

Study Director: Poliana Patah, MD, PhD Bristol-Myers Squibb

More Information
  • Responsible Party: Celgene
  • ClinicalTrials.gov Identifier: NCT04434196 History of Changes
  • Other Study ID Numbers: CC-99282-CLL-001, U1111-1251-4261, 2019-003228-18
  • First Posted: June 16, 2020 Key Record Dates
  • Last Update Posted: August 28, 2020
  • Last Verified: August 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Yes
  • Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Supporting Materials: Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report (CSR), Analytic Code
  • Time Frame: See Plan Description
  • Access Criteria: See Plan Description
  • URL: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Celgene: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Efficacy
    CC-99282
    Obinutuzumab
    Relapsed
    Refractory
    Safety
  • Additional relevant MeSH terms: Leukemia, Lymphocytic, Chronic, B-Cell
    Lymphoma, Non-Hodgkin
    Leukemia, Lymphoid
    Lymphoma
    Leukemia